Skip to content

Pre-Clinical Data

For more information, please contact us.

For more information, please contact us.

The efficacy of Reltecimod was tested in several models of bacterial infections, including: Gram-positive infections (S. pyogenes and S. pneumoniae), Gram-negative infections (E. coli) and mixed infections (intra-abdominal polymicrobial infection). It was tested either as a stand- alone treatment (in S. pyogenes) or in combination with antibiotics in the other infections.  Reltecimod demonstrated increased survival, reduction of systemic and local inflammation and reduced bacterial burden, without compromising cellular and humoral immunity

A. Efficacy in gram positive bacterial infection (Group A. Streptococcus pyogenes; GAS). Administration of a single dose of Reltecimod increased survival, when animals are treated either early or late post infection.

J Infect Dis. 2013 Jun 15;207(12):1869-77

Improved Survival 

Reduction necrosis at the infection site

Reltecimod given post infection improve muscle inflammation and prevents necrosis

B. Efficacy in Gram-negative bacterial infection: Reltecimod protects mice from lethal E. coli peritonitis following its administration with antibiotics at 4 h after E. coli challenge.  *, p‹0.01 vs. PBS or antibiotics alone.

A. Efficacy in polymicrobial infection (cecal ligation and puncture; CLP), a model of mixed bacterial sepsis. Under conditions where antibiotics treatment alone is not sufficient, addition of Reltecimod is synergistic and dramatically improve survival, even at very late time points (12-24 hours) following the infection.

J Infect Dis. 2015 Mar 15;211(6):995-1003